JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company’s pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Metrics to compare | 2126 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2126PeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −8.9x | −0.5x | |
PEG Ratio | −0.06 | 0.02 | 0.00 | |
Price/Book | 0.5x | 3.5x | 2.6x | |
Price / LTM Sales | 4.6x | 11.3x | 3.0x | |
Upside (Analyst Target) | 11.8% | 19.7% | 55.2% | |
Fair Value Upside | Unlock | 5.8% | 9.7% | Unlock |